Drug excretion mediated by a new prototype of polyspecific transporter
- PMID: 7990927
- DOI: 10.1038/372549a0
Drug excretion mediated by a new prototype of polyspecific transporter
Abstract
Cationic drugs of different types and structures (antihistaminics, antiarrhythmics, sedatives, opiates, cytostatics and antibiotics, for example) are excreted in mammals by epithelial cells of the renal proximal tubules and by hepatocytes in the liver. In the proximal tubules, two functionally disparate transport systems are involved which are localized in the basolateral and luminal plasma membrane and are different from the previously identified neuronal monoamine transporters and ATP-dependent multidrug exporting proteins. Here we report the isolation of a complementary DNA from rat kidney that encodes a 556-amino-acid membrane protein, OCT1, which has the functional characteristics of organic cation uptake over the basolateral membrane of renal proximal tubules and of organic cation uptake into hepatocytes. OCT1 is not homologous to any other known protein and is found in kidney, liver and intestine. As OCT1 translocates hydrophobic and hydrophilic organic cations of different structures, it is considered to be a new prototype of polyspecific transporters that are important for drug elimination.
Similar articles
-
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.Mol Cell Biol. 2001 Aug;21(16):5471-7. doi: 10.1128/MCB.21.16.5471-5477.2001. Mol Cell Biol. 2001. PMID: 11463829 Free PMC article.
-
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. J Pharmacol Exp Ther. 1998. PMID: 9808712
-
Cloning and functional expression of a mouse liver organic cation transporter.Hepatology. 1999 May;29(5):1556-62. doi: 10.1002/hep.510290530. Hepatology. 1999. PMID: 10216142
-
Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).J Pharmacol Exp Ther. 2004 Jan;308(1):2-9. doi: 10.1124/jpet.103.053298. Epub 2003 Oct 23. J Pharmacol Exp Ther. 2004. PMID: 14576340 Review.
-
Organic cation transporters in intestine, kidney, liver, and brain.Annu Rev Physiol. 1998;60:243-66. doi: 10.1146/annurev.physiol.60.1.243. Annu Rev Physiol. 1998. PMID: 9558463 Review.
Cited by
-
Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.Diseases. 2024 Mar 21;12(3):63. doi: 10.3390/diseases12030063. Diseases. 2024. PMID: 38534987 Free PMC article. Review.
-
Structural insights into human organic cation transporter 1 transport and inhibition.Cell Discov. 2024 Mar 15;10(1):30. doi: 10.1038/s41421-024-00664-1. Cell Discov. 2024. PMID: 38485705 Free PMC article.
-
Organic cation transporters in psychiatric and substance use disorders.Pharmacol Ther. 2024 Jan;253:108574. doi: 10.1016/j.pharmthera.2023.108574. Epub 2023 Dec 9. Pharmacol Ther. 2024. PMID: 38072333 Free PMC article. Review.
-
Stereoselective Inhibition of High- and Low-Affinity Organic Cation Transporters.Mol Pharm. 2023 Dec 4;20(12):6289-6300. doi: 10.1021/acs.molpharmaceut.3c00691. Epub 2023 Nov 14. Mol Pharm. 2023. PMID: 37962560 Free PMC article.
-
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543963. doi: 10.1101/2023.06.06.543963. bioRxiv. 2023. Update in: Mol Cell. 2024 May 16;84(10):1932-1947.e10. doi: 10.1016/j.molcel.2024.04.008 PMID: 37333090 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Research Materials
